Comprehensive exploration of the genetic contribution of the dopaminergic and serotonergic pathways to psychiatric disorders

Judit Cabana-Domínguez PhD^{1,2,3,4*}, Bàrbara Torrico PhD^{1,2,3,4*}, Andreas Reif PhD⁵, Noèlia Fernández-Castillo PhD^{1,2,3,4&}, Bru Cormand PhD^{1,2,3,4&}

¹Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona, Barcelona, Catalonia, Spain

²Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Instituto de Salud Carlos III, Spain

³Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Catalonia, Spain

⁴Institut de Recerca Sant Joan de Déu (IR-SJD), Esplugues de Llobregat, Catalonia, Spain

⁵Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, University Hospital Frankfurt, Frankfurt am Main, Germany

*These authors have equally contributed to this work

&These authors have equally supervised this work

CORRESPONDING AUTHORS:

Bru Cormand and Noèlia Fernández. Departament de Genètica, Microbiologia i Estadística, Facultat de Biologia, Universitat de Barcelona, Avinguda Diagonal 643, edifici Prevosti, 3^a planta, 08028, Barcelona, Catalonia, Spain. Tel.: (+34) 93 4021013 - 93 4037082. Fax: (+34) 93 4034420;

Email: bcormand@ub.edu; noefernandez@ub.edu

ABSTRACT

Psychiatric disorders are highly prevalent and display considerable clinical and genetic overlap. Dopaminergic and serotonergic neurotransmission have been shown to have an important role in many psychiatric disorders. Here we aim to assess the genetic contribution of these systems to eight psychiatric disorders (ADHD, ANO, ASD, BIP, MD, OCD, SCZ and TS) using publicly available GWAS analyses performed by the Psychiatric Genomics Consortium. To do so, we elaborated four different gene sets using the Gene Ontology and KEGG pathways tools: two 'wide' selections for dopamine (DA) and for serotonin (SERT), and two 'core' selections for the same systems. At the gene level, we found 67 genes from the DA and/or SERT gene sets significantly associated with one of the studied disorders, and 12 of them were associated with two different disorders. Gene-set analysis revealed significant associations for ADHD and ASD with the wide DA gene set, for BIP with the wide SERT gene set, and for MD with both the core DA set and the core SERT set. Interestingly, interrogation of the cross-disorder GWAS meta-analysis displayed association with the wide DA gene set. To our knowledge, this is the first time that these two neurotransmitter systems have systematically been inspected in these disorders. Our results support a cross-disorder contribution of dopaminergic and serotonergic systems in several psychiatric conditions.

INTRODUCTION

Psychiatric disorders represent a major health problem, affecting 29.2% of the worldwide population at some point during their lifetime [1], and are associated with a considerable distress and functional impairment [2]. They constitute a set of complex traits that result from the interaction of genetic and environmental risk factors, with a heritability ranging from 40 to 80%, depending on the disorder, as estimated by twin studies [3].

Interestingly, psychiatric disorders display considerable clinical overlap among them [4–6], and the presence of comorbidity is associated with an increased severity and difficulty of treatment. Recent studies have shown strong genetic correlations among psychiatric phenotypes [7,8], and the latest genome-wide association study (GWAS) meta-analysis conducted on eight psychiatric disorders (attention-deficit hyperactivity disorder (ADHD), anorexia nervosa (ANO), autism spectrum disorder (ASD), bipolar disorder (BIP), major depression (MD), obsessive-compulsive disorder (OCD), schizophrenia (SCZ) and Tourette’s syndrome (TS)) found that 75% of the LD-independent associated regions (109 out of 146) were associated with more than one disorder [9]. These results suggest that the high levels of comorbidity found in psychiatric disorders may be explained, at least in part, by shared genetic risk factors, supporting the existence of a set of genes that confer relatively broad liability to psychiatric disorders [9].

Dopamine (DA) and serotonin (SERT) are two important neurotransmitters that participate in the regulation of a wide range of essential functions of the organism (e.g. motor control, cognition, motivation, regulation of emotions or reward), and have been related to the physiopathology and treatment of many psychiatric disorders.

Dopaminergic dysfunction has been described in ADHD, ASD, OCD, TS, SCZ, mood disorders and substance use disorders (SUD) among others [10]. For example, the positive symptoms of SCZ seem to be associated with hyperdopaminergic neurotransmission, especially in the mesolimbic system, while the negative symptoms and cognitive deficits might be caused by hypodopaminergic activity in the mesocortical pathway [11]. Therefore, most of the antipsychotic treatments block the dopamine D₂ receptor (e.g. chlorpromazine and haloperidol), and some of them are combined with serotonin 5-HT_{2A} receptor antagonists (e.g. clozapine and risperidone). Moreover, several studies have reported a reduction of dopaminergic receptors density in several brain regions of ADHD patients [12], which is in agreement with the mechanism of action of the ADHD treatments, like methylphenidate or amphetamine, that enhance dopamine transmission in prefrontal cortex [13].

Regarding the serotonergic system, there is strong evidence supporting its role in MD and in other mood disorders based on available pharmacological treatments. The serotonin hypothesis of depression postulates that reduced serotonin signaling is a risk factor in its etiology [14,15], what is supported by the most effective antidepressant treatment, based on the use of serotonin selective reuptake inhibitors (SSRIs), which inhibit the serotonin transporter increasing the extracellular levels of the neurotransmitter [16]. However, the causal mechanisms between low serotonin signaling and depression are still unknown. The role of the serotonergic system in other psychiatric disorders like anxiety, SCZ, ADHD or ASD is still unclear and further studies are needed [17]. Even so, all these psychiatric conditions seem to be related to serotonin dysfunction, and many psychotropic drugs interfere more or less directly with this system [18].

Dopaminergic and serotonergic neurotransmission have been widely investigated through candidate-gene association studies in many psychiatric disorders, which have mainly assessed

genetic variants in core genes encoding DA and SERT transporters, receptors and metabolizers [19–22]. One of the most studied genes is *SLC6A3*, encoding the dopaminergic transporter (DAT), with multiple variants mapping at this locus, including rare variants, copy number variations (CNVs), variable number of tandem repeats (VNTRs) and single nucleotide polymorphisms (SNPs) that have been found associated with several psychiatric conditions [23]. Although genetic variants in the serotonin transporter (SERT), encoded by *SLC6A4*, have also been extensively studied in psychiatric behavioral genetics, these different studies failed to obtain consistent results [24]. Interestingly, the outcome of genome-wide association studies (GWAS) evidenced that the classical serotonergic and dopaminergic candidate genes, like transporters (*SLC6A3* and *SLC6A4*) and receptors are not significantly associated with any psychiatric disorder (<https://www.ebi.ac.uk/gwas/home>), with one exception, *DRD2*, that was found associated with both MD and SCZ [25–27].

In this study, we systematically explored the contribution of common variants in genes involved in dopaminergic and serotonergic neurotransmission in eight psychiatric disorders studied individually and in combination, using GWAS data from the Psychiatric Genomics Consortium (PGC).

MATERIALS AND METHODS

DA and SERT gene selection

We first obtained two core gene sets through manual curation (DA core with 13 genes, and SERT core with 20 genes), containing the well-known dopaminergic or serotonergic genes

(neurotransmitter receptors, transporters and enzymes involved in their synthesis or degradation) (Figure 1A).

For a wide selection of genes encoding proteins involved in dopamine and serotonin neurotransmission and signaling pathways we used two main databases, GO and KEGG. We queried the GO database (Gene Ontology Consortium, <http://www.geneontology.org/>, September 2016) by the search terms “dopamine” or “serotonin/serotonergic”. The resulting list of GO terms (89 for dopamine and 78 for serotonin/serotonergic) was filtered to keep only those of “biological process” ontology source and with presence of the search term as part of the GO identifier. Then, we examined the hierarchical tree structure of the GO database to filter out the most specific terms (child terms) that were contained within broader ones (parental terms). The final GO terms selection included: “dopamine transport” (GO:0015872), “dopamine receptor signaling pathway” (GO:0007212), “dopamine receptor binding” (GO:0050780), “synaptic transmission, dopaminergic” (GO:0001963), “dopaminergic neuron axon guidance” (GO:0036514), “dopaminergic neuron differentiation” (GO:0071542), “response to dopamine” (GO:1903350), “dopamine metabolic process” (GO:0042417), “serotonin receptor signaling pathway” (GO:0007210), “serotonin transport” (GO:0006837), “serotonin metabolic process” (GO:0042428) and “serotonin production involved in inflammatory response” (GO:0002351). For the exploration of KEGG pathways (<https://www.genome.jp/kegg/pathway.html>, September 2016) we followed a similar procedure, using the terms “dopamine” or “serotonin” as keywords, and only those pathways more tightly related to neurotransmitters’ function were kept: “dopaminergic synapse” (hsa04728) and “tyrosine metabolism” (hsa00350), and “serotonergic synapse” (hsa04726) and “tryptophan metabolism” (hsa00380). The human entries obtained were then filtered for more inclusive and non-disease pathways.

We elaborated the dopaminergic (DA wide, 275 genes) and serotonergic (SERT wide, 176 genes) gene sets with human genes belonging to the final GO categories plus the selected KEGG pathways. We confirmed that these two lists contained the corresponding core genes. As the summary statistics used in our analyses did not include the X chromosome we filtered out those genes from our gene sets. In the case of DA genes, 10 genes were removed: 2 core genes (*MAOA* and *MAOB*) and 8 other genes from the wide set (*ATP7A*, *AGTR2*, *FLNA*, *GPR50*, *GRIA3*, *HPRT1*, *PPP2R3B* and *VEGFD*). And 8 genes were excluded for SERT: 3 core genes (*MAOA*, *MAOB* and *HTR2C*) and 5 other genes from the wide set (*ATP7A*, *ARAF*, *ASMT*, *CACNA1F* and *GPM6B*) (Figure 1A).

Finally, four gene lists were obtained: i) DA core (11 genes); ii) DA wide (265 genes); iii) SERT core (17 genes); and iv) SERT wide (168 genes) (Figure 1A).

Gene symbols were converted to Entrez gene ID with the DAVID Gene ID Conversion Tool (<https://david.ncifcrf.gov/conversion.jsp>) for downstream analysis.

Data used

We inspected the four DA and SERT gene sets in eight psychiatric disorders and in the meta-analysis of all of them (cross-disorder meta-analysis; CD-MA) [9] using publicly available GWAS summary statistics of attention-deficit hyperactivity disorder (ADHD) [28], anorexia nervosa (ANO) [29], autism spectrum disorder (ASD) [30], bipolar disorder (BIP) [31], major depression (MD) [32], obsessive-compulsive disorder (OCD) [33], schizophrenia (SCZ) [26] and Tourette's syndrome (TS) [34]. All of them were downloaded from the Psychiatric Genomics Consortium (PGC) webpage (<https://www.med.unc.edu/pgc/results-and-downloads/>) (Figure 1B). The MD and CD-MA summary statistics do not include 23andMe data used by the PGC in the MD GWAS.

Gene-based and gene-set association analyses

Gene-based and gene-set association analyses of each phenotype were performed with MAGMA 1.06 [35] using the summary statistics from each individual GWAS meta-analysis and also from the cross-disorder GWAS meta-analysis. For the gene-based analysis the SNP-wise mean model was used, in which the test statistic used was the sum of $-\log(\text{SNP p-value})$ for SNPs located within the transcribed region (defined on NCBI 37.3 gene definitions), with a 0 Kb window around genes. MAGMA accounts for gene size, number of SNPs in a gene and linkage disequilibrium between markers, using as a reference panel the European ancestry samples from the 1000 Genomes Project, phase 3 [36]. The resulting p-values were corrected for multiple testing using False Discovery Rate (5% FDR).

Based on the gene-based p-values we analysed the four sets of genes described above (DA wide, DA core, SERT wide and SERT core). MAGMA applies a competitive test to analyse whether the genes of a gene set are more strongly associated with the trait than other genes, while correcting for a series of confounding effects such as gene length and size of the gene set. In our analyses, only genes on autosomes were included. Multiple testing corrections were performed for each disorder separately. As the Bonferroni correction is quite conservative for gene sets strongly overlapped, we used an empirical multiple testing correction implemented in MAGMA, based on a permutation procedure.

Gene-based Manhattan plot

Results of the gene-based analysis of the cross-disorder meta-analysis were plotted in R using the package “qqman” [37].

MetaXcan analyses

We considered all the SNPs located in each DA and SERT gene to infer whether the genetically determined expression of each of those genes correlates with the phenotypes considered in the study. These analyses were carried out on MetaXcan [38] using the summary statistics of each disorder. Prediction models were constructed considering SNPs located within $\pm 1\text{Mb}$ from the transcription start site (TSS) of each gene and were trained with RNA-Seq data of 13 GTEx (release V7) brain tissues [39]. The SNP covariance matrices were generated using the 1000 Genomes Project Phase 3 [36] EUR genotypes of the prediction model SNPs. For each brain tissue, the threshold for significance was calculated using the Bonferroni correction for multiple testing.

RESULTS

Dopaminergic and serotonergic neurotransmission have been pointed out as involved in many psychiatric disorders. In the present study we aimed to assess the contribution of these two monoaminergic systems to eight different psychiatric disorders (ADHD, ANO, ASD, BIP, MD, OCD, SCZ and TS) as well as to the meta-analysis of all them (CD-MA). For that purpose, we elaborated four different gene sets (DA wide, 265 genes; SERT wide, 168 genes; DA core, 11 genes; and SERT core, 17 genes; Figure 1A and Supplementary Table S1) that were subsequently interrogated in the summary statistics from nine case-control GWAS meta-analyses (Figure 1B). One gene from DA wide (*KIF5C*) and two from SERT wide (*OR11H7* and *OR10J6P*) gene sets were not present in any of the datasets inspected. At the gene-wide level, we found 67 genes from DA and/or SERT gene sets significantly associated (5% FDR) with at least one of the studied disorders (Supplementary Table S2). Interestingly, twelve of these genes were associated with two different disorders, eight of them with SCZ and BIP (Figure 2 and Supplementary Table S2). Eleven out of these twelve genes showed also a significant association with the CD-MA phenotype, *DRD2* from the DA core gene set among them. Interestingly, five out of these twelve genes (*CACNA1C*, *CACNA1D*, *GNAS*, *GRIN2A*

and *ITR3*) belong to both the DA and SERT gene sets, highlighting the importance of those genes that are involved in two monoamine pathways (Supplementary Table S2).

Then, we plotted the gene-based results of the cross-disorder meta-analysis in a Manhattan plot and highlighted the DA core and SERT core genes, to visualize the performance of these genes in the combination of all the psychiatric conditions considered in the study (Figure 3A). As shown in the figure, only the *DRD2* gene overcomes the Bonferroni correction for multiple testing, and *HTR6* surpasses 5% FDR. Then, we repeated the analysis by highlighting the DA and SERT wide genes and found 10 genes with associations that overcome the Bonferroni correction and 32 additional genes overcoming 5% FDR (Figure 3B). Among them, *CACNA1C*, present in both DA and SERT gene lists, was the one showing the strongest association in the cross-disorder meta-analysis (raw $P=8.9E-14$, $P_{adj}=7.8E-11$).

In addition, to identify genes which expression correlates with the phenotypes included in the study, we performed MetaXcan analysis, considering only those phenotypes that show significant association with DA or SERT genes (ADHD, ASD, MD, SCZ and CD-MA). Taking in account the genes associated at gene level with a given disorder, we found that the expression of *CTNNB1* significantly correlates with ADHD in the amygdala ($P=8.9E-04$, $Z=-3.3246$), *ATF6B* with SCZ in the spinal cord ($P=1.6E-06$, $Z=4.7925$) and *DNM1* and *ITPR3* with the phenotype in the CD-MA in the cortex and caudate, respectively ($P=2.6E-04$, $Z=3.6516$ and $P=1.8E-05$, $Z=-4.2860$) (Table 1 and Supplementary Tables S3-S15). Interestingly, the expression of the *DNM1* gene in the cortex also correlates with ADHD ($P=8.5E-03$, $Z=2.6308$), ASD ($P=5.9E-03$, $Z=2.7524$), MD ($P=3.0E-03$, $Z=2.9630$) and SCZ ($P=0.0312$, $Z=2.1549$) in the same direction, and this gene was found nominally associated with all these disorders in the gene-based analysis (raw $P_{ADHD}=2.5E-04$, raw $P_{ASD}=3.6E-03$, raw $P_{MD}=1.5E-03$ and raw $P_{SCZ}=0.0156$). It is important to note that for most DA and SERT

genes (ranging from 77% to 93.6% depending on the tissue and disorder) we could not retrieve information from MetaXcan because it only provides data about those gene models where the predictive power is good enough.

Finally, we performed a gene-set analysis that revealed interesting significant associations. The DA wide gene set was significantly associated with ADHD ($P_{\text{perm}}=0.023$) and ASD ($P_{\text{perm}}=0.025$), and the SERT wide gene set with BIP ($P_{\text{perm}}=0.015$). Besides, both the DA core ($P_{\text{perm}}=7.1\text{E-}03$) and the SERT core ($P_{\text{perm}}=0.021$) gene sets were significantly associated with MD (Figure 4 and Supplementary Table S16). Interrogation of the cross-disorder GWAS meta-analysis displayed association with the DA wide gene set ($P_{\text{perm}}=0.044$). It should be mentioned that the DA wide gene set was nominally associated also with BIP, TS and SCZ, in line with the results obtained in the cross-disorder analysis for this neurotransmitter system (Figure 4). No significant results were found for ANO, OCD and TS neither in the gene-based nor in the gene-set analyses after multiple testing correction, maybe due to limited sample sizes (number of patients below 5000; Figure 1B).

DISCUSSION

Dopaminergic (DA) and serotonergic (SERT) functions represent good candidates for psychiatric disorders, mainly on the basis of the effectiveness of several pharmacological treatments and their target molecules [10,23,40–42]. Common genetic variation of genes encoding key participants of these two neurotransmission systems (receptors, transporters and enzymes) has been broadly studied in psychiatric disorders, mainly through candidate-gene association studies, with several positive findings [23,43–45]. However, except for a few cases [25–27], these hits have not been replicated by GWAS, which raises questions on how alterations in these two neurotransmitter

systems can actually be causally related to psychiatric conditions, but also on the value of genome-wide significance for functional variation [46].

To our knowledge, this is the first systematic study of the DA and SERT neurotransmitter systems in eight psychiatric disorders (ADHD, ANO, ASD, BIP, MD, OCD, SCZ and TS) using data from GWAS meta-analyses that include large number of samples. Here, we assess the contribution of genetic variation not only of genes encoding the core participants of DA and SERT functions, but also of a comprehensive list of genes involved in DA and SERT neurotransmission obtained by a systematic database search.

Our results show a contribution to psychiatric disorders of both dopaminergic and serotonergic systems at genetic level. We found several DA and SERT genes associated with some psychiatric disorders, twelve of them with two conditions, and also in the cross-disorder meta-analysis, which underscores the relevance of genetic risk factors in these genes for psychiatric disorders. Among the associated genes we identified the DA core gene coding for the dopamine receptor D2, *DRD2*, which has been widely studied as a candidate for different psychiatric disorders with some positive findings [47–51], especially in SCZ (recently meta-analyzed by [52]). The association between *DRD2* and SCZ observed through candidate-gene studies has subsequently been confirmed through GWAS [26]. Interestingly, a recent GWAS identified association of polymorphisms in *DRD2* with depressive symptoms, neuroticism and different traits of the well-being spectrum [53,54]. These findings are in agreement with ours, obtaining associations of *DRD2* with SCZ and MD (Figure 2 and Supplementary Table S2). Another interesting gene that encodes the calcium voltage-gated channel subunit alpha1 C (*CACNA1C*), present in both the DA and SERT wide gene lists and found associated by us with BIP and with SCZ (disorders with a very high genetic correlation, $r_g=0.7$ [9]), displayed the strongest association in the cross-disorder meta-

analysis. Noteworthy, *CACNA1C* polymorphisms have been consistently associated with BIP and SCZ, among other psychiatric disorders [55,56]. Mutations in this gene have been related with Timothy Syndrome, a monogenic disorder that affects multiple organs and presents with cognitive impairment, major developmental delays, and autism-like behaviours [57]. We also identified the potassium calcium-activated channel subfamily N member 2 (*KCNN2*) gene, from the SERT wide gene set, associated with BIP and with ASD, as previously described in two studies [30,31].

Interestingly, two genes emerged from the analysis of gene expression using MetaXcan. First, the gene for inositol 1,4,5-trisphosphate receptor type 3 (*ITPR3*), found associated with ADHD, SCZ and the CD-MA at gene level in our study, which expression would be altered in the caudate of patients from the CD-MA. The caudate nucleus is a crucial component of the ventral striatum, part of the basal ganglia that control motor, cognitive control, motivational and emotional processing [58], functions involved in the physiopathology of many psychiatric conditions. Several studies have found alterations both in the volume of the caudate nucleus and in its functional connections with other brain regions in many psychiatric disorders [59–61]. Interestingly, the *ITPR3* gene has been associated to type 1 diabetes [62], which curiously shows a correlation with risk of ADHD in the offspring [63–65]. The other gene that was pointed by this analysis was dynamin 1 (*DNM1*), which expression significantly correlates not only with the CD-MA, but also with ADHD, ASD, MD and SCZ, in all cases in the cortex and in the same direction. Rare variants in *DNM1* have been identified in patients with a mendelian phenotype, epileptic encephalopathy [66], and in some cases of intellectual disability with seizures [67].

In the cross-disorder meta-analysis study [9], the eight psychiatric disorders used were classified in three groups using exploratory factor analysis (EFA): disorders characterized by compulsive/perfectionistic behaviors (AN, OCD and TS), mood and psychotic disorders (MD, BIP

and SCZ), and early-onset neurodevelopmental disorders (ASD, ADHD, TS, as well as MD). Our results are in line with this classification, as we identified association of the serotonergic gene sets with BIP and MD, included in the same group, whereas the dopaminergic set was associated with ADHD, ASD and MD, the three disorders conforming the third factor. Interestingly, MD showed association with both the SERT and the DA core gene sets and, in parallel, it represents a shared disorder between two different factors of the CD-MA.

Although SERT dysfunction has been proposed to be the common denominator in a wide range of neuropsychiatric illnesses [66], our gene-set results link this neurotransmitter system only with BIP (wide gene set) and with MD (core gene set). SERT signaling has been associated with concrete alterations in the intrinsic activity of the brain: an increase of the default-mode network and a decrease of the sensorimotor network. Interestingly, MD is characterized by an increase of internally focused thoughts and an inhibited psychomotor behavior and affectivity, an imbalance that has been also detected in BIP [66], but not in SCZ, the third of this genetically-correlated group of psychiatric disorders [9].

Gene-set analysis of the DA system showed association of the wide selection with ADHD and with ASD, two disorders that co-occur frequently [68] and with a high genetic correlation ($r_g = 0.37$) [9]. Association of dopaminergic genes with these psychiatric conditions, especially the DA core genes, has been broadly studied using different strategies, including candidate-gene association studies or exome/genome sequencing [69–72]. Besides, the DA core gene set was significantly associated with MD. Noteworthy, many of the depressive symptoms have been consistently associated with dopaminergic dysfunction [73,74]. Interestingly, the cross-disorder meta-analysis displayed association with the DA wide gene set, underscoring the importance that this neurotransmitter has in many psychiatric disorders [75,76].

Some strengths and limitations of our study should be discussed. We performed a systematic study of the dopaminergic and serotonergic neurotransmitter systems in eight psychiatric disorders and the meta-analysis of all of them. At gene level, we identified twelve genes significantly associated with several disorders. However, none of them was associated in more than two disorders, being BIP and/or SCZ one of these disorders in most cases (10 out to 12). This brings up the issue that these two disorders could drive some of the results obtained because of their large sample sizes. In addition, DA and SERT neurotransmission are functionally interconnected and some genes participate in both pathways (about 20% of genes in the DA gene sets are also in SERT, and 32% the other way round). This could have some impact in the results obtained in the gene-set analysis. In addition, is important to note that these pathways are still not very well defined and we might be missing information from some genes. On the other hand, as MetaXcan only provides information about those gene models where the predictive power is good enough, we could not retrieve information from most DA and SERT genes. Finally, it is important to note that no significant results were found for ANO, OCD and TS neither in the gene-based nor in the gene-set analyses, maybe due to limited sample sizes. In these disorders, further studies should be done with larger samples.

To our knowledge, this is the first systematic genetic study of the dopaminergic and serotonergic neurotransmitter systems in eight psychiatric disorders (ADHD, ANO, ASD, BIP, MD, OCD, SCZ and TS) and in the meta-analysis of all of them. At gene level, we identified association of 67 DA and/or SERT genes with at least one of the studied disorders, twelve of them associated with two conditions. Gene-set analysis revealed significant associations with the DA gene sets for ADHD, ASD, MD and the cross-disorder GWAS meta-analysis, and with SERT gene sets for MD and BIP. The results obtained support a cross-disorder contribution of these two neurotransmitters systems in several psychiatric conditions.

FUNDING AND DISCLOSURE

Major financial support for this research was received by BC from the Spanish 'Ministerio de Ciencia, Innovación y Universidades' (RTI2018-100968-B-100), 'Ministerio de Economía y Competitividad' (SAF2015-68341-R) and 'AGAUR/Generalitat de Catalunya' (2017-SGR-738). The research leading to these results has also received funding from the European Union H2020 Program [H2020/2014-2020] under grant agreements n° 667302 (CoCA), 643051 (MiND) and 728018 (Eat2beNICE) by BC and Federal Ministry of Education and Research (BMBF, grant number: 01EE1404A) by AR. BT and JC-D were supported by the H2020 CoCA project, and NF-C by 'Centro de Investigación Biomédica en Red de Enfermedades Raras' (CIBERER) and by an EMBO short-term fellowship (ASTF 573-2016).

The authors declare no conflict of interests. This publication reflects only the author's view and the European Commission is not responsible for any use that may be made of the information it contains.

ACKNOWLEDGMENTS

The authors thank the PGC ADHD, ANO, ASD, BIP, MD, OCD, SCZ, TS and cross-disorder working groups for making accessible the data from their studies.

AUTHOR CONTRIBUTIONS

AR, NF-C and B.C conceived and designed the study. JC-D and BT obtained the data, performed the

bioinformatic analyses and wrote the manuscript. JC-D, BT and NF-C prepared Figures and Tables. BC and NF-C coordinated the study and supervised the manuscript preparation. All authors contributed to and approved the final manuscript.

REFERENCES

1. Steel Z, Marnane C, Iranpour C, Chey T, Jackson JW, Patel V, et al. The global prevalence of common mental disorders: A systematic review and meta-analysis 1980-2013. *Int J Epidemiol*. 2014;43:476–493.
2. Whiteford HA, Degenhardt L, Rehm J, Baxter AJ, Ferrari AJ, Erskine HE, et al. Global burden of disease attributable to mental and substance use disorders: Findings from the Global Burden of Disease Study 2010. *Lancet*. 2013;382:1575–1586.
3. Polderman TJC, Benyamin B, De Leeuw CA, Sullivan PF, Van Bochoven A, Visscher PM, et al. Meta-analysis of the heritability of human traits based on fifty years of twin studies. *Nat Genet*. 2015;47:702–709.
4. Andrews G, Slade T, Issakidis C. Deconstructing current comorbidity: data from the Australian National Survey of Mental Health and Well-Being. *Br J Psychiatry*. 2002;181:306–314.
5. Plana-Ripoll O, Pedersen CB, Holtz Y, Benros ME, Dalsgaard S, de Jonge P, et al. Exploring Comorbidity Within Mental Disorders Among a Danish National Population. *JAMA Psychiatry*. 2019;76:259.
6. Bijl R V, Ravelli A, van Zessen G. Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). *Soc Psychiatry Psychiatr Epidemiol*. 1998;33:587–595.
7. Martin J, Taylor MJ, Lichtenstein P. Assessing the evidence for shared genetic risks across psychiatric disorders and traits. *Psychol Med*. 2018;48:1759–1774.

8. Brainstorm Consortium TB, Anttila V, Bulik-Sullivan B, Finucane HK, Walters RK, Bras J, et al. Analysis of shared heritability in common disorders of the brain. *Science*. 2018;360.
9. Lee. PH, Cross-Disorder Group of the Psychiatric Genomics Consortium V, Won H, Feng Y-CA, Rosenthal J, Zhu Z, et al. Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. *Cell*. 2019;179:1469-1482.e11.
10. Ayano G. Dopamine: Receptors, Functions, Synthesis, Pathways, Locations and Mental Disorders: Review of Literatures. *J Ment Disord Treat*. 2016;2:1–4.
11. Li P, L. Snyder G, E. Vanover K. Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future. *Curr Top Med Chem*. 2016;16:3385–3403.
12. Tripp G, Wickens JR. Neurobiology of ADHD. *Neuropharmacology*. 2009;57:579–589.
13. Sharma A, Couture J. A Review of the Pathophysiology, Etiology, and Treatment of Attention-Deficit Hyperactivity Disorder (ADHD). *Ann Pharmacother*. 2014;48:209–225.
14. Albert PR, Benkelfat C. The neurobiology of depression-revisiting the serotonin hypothesis. II. Genetic, epigenetic and clinical studies. *Philos Trans R Soc B Biol Sci*. 2013;368.
15. Coppen A. The biochemistry of affective disorders. *Br J Psychiatry*. 1967;113:1237–1264.
16. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. *Lancet*. 2018;391:1357–1366.
17. Lin SH, Lee LT, Yang YK. Serotonin and mental disorders: A concise review on molecular neuroimaging evidence. *Clin Psychopharmacol Neurosci*. 2014;12:196–202.
18. Marazziti D. Understanding the role of serotonin in psychiatric diseases. *F1000Research*. 2017;6:180.
19. Gizer IR, Ficks C, Waldman ID. Candidate gene studies of ADHD: A meta-analytic review. *Hum Genet*. 2009;126:51–90.
20. Talkowski ME, Bamne M, Mansour H, Nimgaonkar VL. Dopamine genes and schizophrenia:

Case closed or evidence pending? Schizophr Bull. 2007;33:1071–1081.

21. Sampaio AS, Lins RMP, Daltro-Oliveira R, De Quarantini LC, Do Rosário MC, Miguel EC, et al. Genetic association studies in obsessive-compulsive disorder. Arch Clin Psychiatry. 2013;40:177–190.
22. Gatt JM, Burton KLO, Williams LM, Schofield PR. Specific and common genes implicated across major mental disorders: A review of meta-analysis studies *. 2014. 2014. <https://doi.org/10.1016/j.jpsychires.2014.09.014>.
23. Salatino-Oliveira A, Rohde LA, Hutz MH. The dopamine transporter role in psychiatric phenotypes. Am J Med Genet Part B Neuropsychiatr Genet. 2018;177:211–231.
24. Margoob MA, Mushtaq D. Serotonin transporter gene polymorphism and psychiatric disorders: is there a link? Indian J Psychiatry. 2011;53:289–299.
25. Pardiñas AF, Holmans P, Pocklington AJ, Escott-Price V, Ripke S, Carrera N, et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat Genet. 2018;50:381–389.
26. Ripke S, Neale BM, Corvin A, Walters JTR, Farh KH, Holmans PA, et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–427.
27. Howard DM, Adams MJ, Clarke TK, Hafferty JD, Gibson J, Shireli M, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci. 2019;22:343–352.
28. Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat Genet. 2019;51:63–75.
29. Duncan L, Yilmaz Z, Gaspar H, Walters R, Goldstein J, Anttila V, et al. Significant Locus and Metabolic Genetic Correlations Revealed in Genome-Wide Association Study of Anorexia Nervosa. Am J Psychiatry. 2017;174:850–858.
30. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of common genetic risk variants for autism spectrum disorder. Nat Genet. 2019;51:431–444.

31. Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V, et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. *Nat Genet.* 2019;51:793–803.
32. Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. *Nat Genet.* 2018;167577.
33. Arnold PD, Askland KD, Barlassina C, Bellodi L, Bienvenu OJ, Black D, et al. Revealing the complex genetic architecture of obsessive-compulsive disorder using meta-analysis. *Mol Psychiatry.* 2018;23:1181–1188.
34. Yu D, Sul JH, Tsetsos F, Nawaz MS, Huang AY, Zelaya I, et al. Interrogating the Genetic Determinants of Tourette’s Syndrome and Other Tic Disorders Through Genome-Wide Association Studies. *Am J Psychiatry.* 2019;176:217–227.
35. Willer CJ, Li Y, Abecasis GR. METAL: Fast and efficient meta-analysis of genomewide association scans. *Bioinformatics.* 2010;26:2190–2191.
36. Auton A, Abecasis GR, Altshuler DM, Durbin RM, Abecasis GR, Bentley DR, et al. A global reference for human genetic variation. *Nature.* 2015;526:68–74.
37. Turner SD. qqman: an R package for visualizing GWAS results using Q-Q and manhattan plots. *BioRxiv.* 2014:005165.
38. Barbeira AN, Dickinson SP, Bonazzola R, Zheng J, Wheeler HE, Torres JM, et al. Exploring the phenotypic consequences of tissue specific gene expression variation inferred from GWAS summary statistics. *Nat Commun.* 2018;9:1825.
39. GTEx Consortium, Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, et al. The Genotype-Tissue Expression (GTEx) project. *Nat Publ Gr.* 2013;45:580–585.
40. Yokokura M, Terada T, Bunai T, Nakaizumi K, Kato Y, Yoshikawa E, et al. Alterations in serotonin transporter and body image-related cognition in anorexia nervosa. *NeuroImage Clin.* 2019;23:101928.
41. Mohammadi A, Rashidi E, Amooeian VG. Brain, blood, cerebrospinal fluid, and serum

biomarkers in schizophrenia. *Psychiatry Res.* 2018.

42. Banerjee E, Nandagopal K. Does serotonin deficit mediate susceptibility to ADHD? *Neurochem Int.* 2015.
43. Sinopoli VM, Burton CL, Kronenberg S, Arnold PD. A review of the role of serotonin system genes in obsessive-compulsive disorder. *Neurosci Biobehav Rev.* 2017.
44. Hou Y, Xiong P, Gu X, Huang X, Wang M, Wu J. Association of Serotonin Receptors with Attention Deficit Hyperactivity Disorder: A Systematic Review and Meta-analysis. *Curr Med Sci.* 2018;38:538–551.
45. Zai G, Barta C, Cath D, Eapen V, Geller D, Grünblatt E. New insights and perspectives on the genetics of obsessive-compulsive disorder. *Psychiatr Genet.* 2019;29:142–151.
46. Boyle EA, Li YI, Pritchard JK. An Expanded View of Complex Traits: From Polygenic to Omnigenic. *Cell.* 2017;169:1177–1186.
47. Paschou P. The genetic basis of Gilles de la Tourette Syndrome. *Neurosci Biobehav Rev.* 2013.
48. Li MD, Ma JZ, Beuten J. Progress in searching for susceptibility loci and genes for smoking-related behaviour. *Clin Genet.* 2004;66:382–392.
49. Rady A, Elsheshai A, Mokhtar M, Abou el Wafa H, Elkholy O. The A1 allele of the DRD2 TaqA1/A2 polymorphism as risk factor for PTSD. *Eur J Psychiatry.* 2011;25:144–149.
50. Nisoli E, Brunani A, Borgomainerio E, Tonello C, Dioni L, Briscini L, et al. D2 dopamine receptor (DRD2) gene Taq1A polymorphism and the eating-related psychological traits in eating disorders (anorexia nervosa and bulimia) and obesity. *Eat Weight Disord - Stud Anorexia, Bulim Obes.* 2007;12:91–96.
51. Colizzi M, Iyegbe C, Powell J, Ursini G, Porcelli A, Bonvino A, et al. Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis. *Schizophr Bull.* 2015;41:1171–1182.
52. He H, Wu H, Yang L, Gao F, Fan Y, Feng J, et al. Associations between dopamine D2 receptor gene polymorphisms and schizophrenia risk: a PRISMA compliant meta-analysis.

Neuropsychiatr Dis Treat. 2016;12:3129–3144.

53. Baselmans BML, Jansen R, Ip HF, van Dongen J, Abdellaoui A, van de Weijer MP, et al. Multivariate genome-wide analyses of the well-being spectrum. *Nat Genet.* 2019;51:445–451.
54. Nagel M, Jansen PR, Stringer S, Watanabe K, De Leeuw CA, Bryois J, et al. Meta-analysis of genome-wide association studies for neuroticism in 449,484 individuals identifies novel genetic loci and pathways. *Nat Genet.* 2018;50:920–927.
55. Heyes S, Pratt WS, Rees E, Dahimene S, Ferron L, Owen MJ, et al. Genetic disruption of voltage-gated calcium channels in psychiatric and neurological disorders. *Prog Neurobiol.* 2015;134:36–54.
56. Moon AL, Haan N, Wilkinson LS, Thomas KL, Hall J. CACNA1C: Association With Psychiatric Disorders, Behavior, and Neurogenesis. *Schizophr Bull.* 2018;44:958–965.
57. Splawski I, Timothy KW, Sharpe LM, Decher N, Kumar P, Bloise R, et al. CaV1.2 Calcium Channel Dysfunction Causes a Multisystem Disorder Including Arrhythmia and Autism. *Cell.* 2004;119:19–31.
58. Lanciego JL, Luquin N, Obeso JA. Functional neuroanatomy of the basal ganglia. *Cold Spring Harb Perspect Med.* 2012;2:a009621.
59. Duan M, Chen X, He H, Jiang Y, Jiang S, Xie Q, et al. Altered Basal Ganglia Network Integration in Schizophrenia. *Front Hum Neurosci.* 2015;9:561.
60. Macpherson T, Hikida T. Role of basal ganglia neurocircuitry in the pathology of psychiatric disorders. *Psychiatry Clin Neurosci.* 2019;73:289–301.
61. Ring HA, Serra-Mestres J. Neuropsychiatry of the basal ganglia. *J Neurol Neurosurg Psychiatry.* 2002;72:12–21.
62. Roach JC, Deutsch K, Li S, Siegel AF, Bekris LM, Einhaus DC, et al. Genetic mapping at 3-kilobase resolution reveals inositol 1,4,5-triphosphate receptor 3 as a risk factor for type 1 diabetes in Sweden. *Am J Hum Genet.* 2006;79:614–627.
63. Xiang AH, Wang X, Martinez MP, Getahun D, Page KA, Buchanan TA, et al. Maternal

gestational diabetes mellitus, type 1 diabetes, and type 2 diabetes during pregnancy and risk of ADHD in offspring. *Diabetes Care*. 2018;41:2502–2508.

64. Ji J, Chen T, Sundquist J, Sundquist K. Type 1 diabetes in parents and risk of attention deficit/hyperactivity disorder in offspring: A population-based study in Sweden. *Diabetes Care*. 2018;41:770–774.
65. Nielsen PR, Benros ME, Dalgaard S. Associations Between Autoimmune Diseases and Attention-Deficit/Hyperactivity Disorder: A Nationwide Study. *J Am Acad Child Adolesc Psychiatry*. 2017;56:234-240.e1.
66. Appenzeller S, Balling R, Barisic N, Baulac S, Caglayan H, Craiu D, et al. De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. *Am J Hum Genet*. 2014. 2014. <https://doi.org/10.1016/j.ajhg.2014.08.013>.
67. Fitzgerald TW, Gerety SS, Jones WD, Van Kogelenberg M, King DA, McRae J, et al. Large-scale discovery of novel genetic causes of developmental disorders. *Nature*. 2015;519:223–228.
68. Antshel KM, Zhang-James Y, Wagner KE, Ledesma A, Faraone S V. An update on the comorbidity of ADHD and ASD: A focus on clinical management. *Expert Rev Neurother*. 2016;16:279–293.
69. Faraone S V., Larsson H. Genetics of attention deficit hyperactivity disorder. *Mol Psychiatry*. 2019;24:562–575.
70. Hamilton PJ, Campbell NG, Sharma S, Erreger K, Herborg Hansen F, Saunders C, et al. De novo mutation in the dopamine transporter gene associates dopamine dysfunction with autism spectrum disorder. *Mol Psychiatry*. 2013;18:1315–1323.
71. Hettinger JA, Liu X, Hudson ML, Lee A, Cohen IL, Michaelis RC, et al. DRD2 and PPP1R1B (DARPP-32) polymorphisms independently confer increased risk for autism spectrum disorders and additively predict affected status in male-only affected sib-pair families. *Behav Brain Funct*. 2012;8:19.
72. Gadow KD, Pinsonneault JK, Perlman G, Sadee W. Association of dopamine gene variants, emotion dysregulation and ADHD in autism spectrum disorder. *Res Dev Disabil*.

2014;35:1658–1665.

73. Grace AA. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. *Nat Rev Neurosci*. 2016;17:524–532.
74. Belujon P, Grace AA. Dopamine System Dysregulation in Major Depressive Disorders. *Int J Neuropsychopharmacol*. 2017;20:1036–1046.
75. Schmidt WJ, Reith MEA. Dopamine and glutamate in psychiatric disorders. 2005.
76. Ptáček R, Kuzelová H, Stefano GB. Dopamine D4 receptor gene DRD4 and its association with psychiatric disorders. *Med Sci Monit*. 2011;17:RA215-20.
77. Zohar J, Stahl S, Moller HJ, Blier P, Kupfer D, Yamawaki S, et al. A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. *Eur Neuropsychopharmacol*. 2015;25:2318–2325.

Figure 1. (A) Strategy for the selection of the serotonin (SERT) and dopamine (DA) gene sets using Gene Ontology and KEGG’s pathways for the wide sets and manual curation for the core sets. All genes of the core gene sets are also included in their corresponding wide gene set. (B) Description of samples used in this study. The area of the circles is proportional to the sample size of the disorder.

Figure 2. Venn diagram of the significantly associated DA and SERT genes across the studied disorders (5% False Discovery Rate). Gene names are only provided for those genes significantly associated with more than one disorder (overlapping genes). All the genes overlapping across phenotypes are significantly associated with the phenotype in the cross-disorder meta-analysis, except for *GNAS*. The area of circles is proportional to the number of significantly associated genes in each disorder. DA: dopaminergic gene set; SERT: serotonergic gene set. ADHD: Attention-Deficit/Hyperactivity Disorder; ASD: Autism Spectrum Disorder; BIP: Bipolar Disorder; MD: Major Depression; SCZ: Schizophrenia.

Figure 3. Manhattan plots of the gene-based p-values in the cross-disorder meta-analysis. Represented A) DA core and SERT core genes, and B) DA wide and SERT wide gene sets. Colored dots correspond to DA genes in pink, SERT genes in blue and overlapping genes in purple. Continuous line: threshold for Bonferroni significance ($P = 2.8E-06$). Discontinuous line: threshold for 5% False Discovery Rate ($P = 4.9E-03$).

Figure 4. Results of the MAGMA gene-set association analysis on every phenotype under study. A small circle represents nominally significant p-value, a big circle represents significant p-value after the empirical multiple testing correction implemented in MAGMA. DA: dopaminergic gene set; SERT: serotonergic gene set. ADHD: Attention-Deficit/Hyperactivity Disorder; ANO: Anorexia Nervosa; ASD: Autism Spectrum Disorder; BIP: Bipolar Disorder; MD: Major Depression; OCD: Obsessive-Compulsive Disorder; TS: Tourette’s Syndrome; SCZ: Schizophrenia; CD-MA: Cross-Disorder.

Table 1. MetaXcan prediction of gene expression effects on the studied disorders for multiple brain tissues.

medRxiv preprint doi: <https://doi.org/10.1101/2020.06.30.20143404>; this version posted July 3, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Gene symbol	entrezID	Gene sets		Brain tissue ^{&}	Disorder	Z-score	p-value	N SNPs in model	N SNPs used	Predicted R ²
<i>ATF6B</i>	1388	DA		Spinal cord	SCZ	4.7924	1.6E-06	11	5	0.1466
<i>CACNA1C</i>	775	DA	SERT	Cerebellum	CD-MA	-3.0166	2.6E-03	51	41	0.2435
					SCZ	-2.4867	0.0129	51	50	0.2435
<i>CACNA1D</i>	776	DA	SERT	Cerebellar hemisphere	ADHD	-2.2252	0.0261	107	89	0.0988
<i>CTNNB1</i>	1499	DA		Amygdala	ADHD	-3.3246	8.9E-04	36	35	0.1692
				Caudate	ADHD	-2.8011	5.1E-03	12	12	0.0789
				Putamen	ADHD	-3.0637	2.2E-03	28	27	0.1740
				Spinal cord	ADHD	-2.2299	0.0258	47	32	0.1377
<i>CYP2D6</i>	1565		SERT	Amygdala	CD-MA	2.5247	0.1158	15	15	0.2419
					SCZ	2.3181	0.0204	15	15	0.2419
<i>DNM1</i>	1759	DA		Cortex	ADHD	2.6308	8.5E-03	3	3	0.0502
					ASD	2.7524	5.9E-03	3	3	0.0502
					CD-MA	3.6516	2.6E-04	3	3	0.0502
					MD	2.9630	3.0E-03	3	3	0.0502
					SCZ	2.1548	0.0312	3	3	0.0502
<i>FLOT1</i>	10211	DA		Cerebellar hemisphere	SCZ	-2.2126	0.0269	79	5	0.1378
<i>GCH1</i>	2643	DA		Cerebellum	SCZ	-1.1404	0.0490	103	102	0.0552
<i>GNB2</i>	2783		SERT	Spinal cord	CD-MA	-2.8822	3.9E-03	31	29	0.0579
<i>GRIN2A</i>	2903	DA	SERT	Spinal cord	BIP	-2.6559	7.9E-03	3	3	0.2636
<i>HTR6</i>	3362		SERT*	Anterior cingulate	BIP	2.4006	0.0164	58	58	0.0968
					CD-MA	2.4828	0.1303	58	49	0.0968
<i>ITPR3</i>	3710	DA	SERT	Caudate	CD-MA	-4.2860	1.8E-05	4	4	0.0867
<i>MAPK3</i>	5595		SERT	Hippocampus	SCZ	2.0050	0.0449	17	17	0.0734
<i>MAPK10</i>	5602	DA		Anterior cingulate	BIP	2.3373	0.0194	15	15	0.1481
					CD-MA	2.8561	0.0344	15	15	0.1481
				Caudate	BIP	2.0394	0.0414	39	39	0.1546
					CD-MA	2.1152	0.0344	39	32	0.1546
				Cortex	BIP	2.6829	7.3E-03	28	28	0.0880
					CD-MA	2.6987	7.0E-03	28	22	0.0880
				Nucleus accumbens	BIP	2.1524	0.0314	35	35	0.1187
					CD-MA	2.3767	0.0175	35	33	0.1187

[&]Prediction models were only available for some tissues and genes; Z-score: Number of standard deviations change in gene expression; p-value: Significance of the association between predicted expression levels and the disorder; N SNPs in model: Number of SNPs used in the training of prediction models for each gene; N SNPs used: Number of SNPs used from the corresponding GWAS summary statistics; Predicted R²: Correlation between the predicted and observed gene expression during prediction model training; DA: Wide dopaminergic gene set; SERT: Wide serotonergic gene set. * Gene present in SERT core gene set. ADHD: Attention-Deficit/Hyperactivity Disorder; ASD: Autism Spectrum Disorder; BIP: Bipolar Disorder; MD: Major Depression; SCZ: Schizophrenia; CD-MA: Cross-Disorder meta-analysis. In bold: Significant p-values overcoming Bonferroni correction for multiple testing.